ClinicalTrials.gg
CompletedNCT04417972Updated Jul 8, 2024

The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis.

A Phase 1/2 interventional study of SHR7280 and Placebo oral tablet in Endometriosis, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-07-08.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
179
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Endometriosis with a site in China — 16 open to participants now, 17 under way, 2 of them phase 3. Endometriosis · China.

Enrollment
14th of 28
179 · median 161
Started
2020
with 2 others
Phase 1/2
Only one
of the 47
Registered
17th of 47
by date
Lead sponsor
4 of 47
Jiangsu HengRui Medicine Co., Ltd.

Among the 47 studies in Endometriosis with a site in China, this one is the 14th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2020, is the only one in phase 1/2, and was the 17th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

16 of the 47 studies in Endometriosis with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Endometriosis with a site in China, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR7280 tablets in premenopausal subjects with endometriosis. In addition, this study will provide information on efficacy of SHR7280 tablets in premenopausal subjects with endometriosis.

Read the detailed description

Endometriosis is a common disease, affecting 5-10% of women of reproductive age . It is an estrogen-dependent and estrogen-driven disease and so hormonal manipulation and suppression of estrogen production form the basis of the majority of medical treatment. The primary objective of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR7280 tablets in premenopausal subjects with endometriosis. In addition, this study will provide information on efficacy of SHR7280 tablets in premenopausal subjects with endometriosis.

03

Conditions studied

  • Endometriosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase I/II

  1. premenopausal females, aged 18-45
  2. History of regular menstrual cycles
  3. Endometriosis participant diagnosed by surgical (e.g., laparoscopy or laparotomy) or by magnetic resonance imaging or ultrasonography.
  4. Participant must agree to use only protocol specified rescue analgesics during the Screening and Treatment Periods for endometriosis-associated pain.
  5. Participant in general good health. No findings in laboratory parameters or clinically significant abnormality on X-ray Phase I (only) Participant has mild or moderate pelvic pain associated with endometriosis at Screening.

Phase II(only) Participant has moderate or severe pelvic pain associated with endometriosis at Screening.

Exclusion criteria

Exclusion Criteria:

Phase I/II

  1. Subjects with severe trauma or surgery within 6 months prior to the screening;
  2. Known blood donation within 30 days pre-dose; donating≥200 ml of blood 2 months pre-dose;
  3. Pregnant or Serum β-human chorionic gonadotropin (hCG)> 5 Million International Units(mIU)/mL at screening or baseline
  4. Pregnant or breast feeding ;
  5. Have pelvic pain that is not caused by endometriosis
  6. Abnormal uterine bleeding
  7. Are currently receiving gonadotropin-releasing hormone (GnRH) agonist, a GnRH antagonist or danazol or have received any of these agents within 6 months of the start of screening.
  8. Are currently receiving subcutaneous medroxyprogesterone acetate (DMPA-SC) or intramuscular medroxyprogesterone acetate (DMPA-IM) or have received any of these agents within 3 months of the start of screening.
  9. Are currently using hormonal or other forms of hormonal therapy or received such treatment within 2 months of the start of screening.

Phase I (only) one month prior to screening involved in any drug or medical device clinical subjects, or within 5 half-life of drugs before screening; Phase II (only) Screening dual-energy x-ray absorptiometry (DXA) scan results of the lumbar spine, femoral neck, or total hip bone mineral density corresponding to 1.5 or more standard deviations below normal (T-score at or below -1.5)

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
179 participants (actual)

Study arms

  • Experimental
    SHR7280 dose 1

    oral administration for 21days,Phase I

    Drug: SHR7280 · Drug: Placebo oral tablet

  • Experimental
    SHR7280 dose 2

    oral administration for 21days,Phase I

    Drug: SHR7280 · Drug: Placebo oral tablet

  • Experimental
    SHR7280 dose 3

    oral administration for 21days,Phase I

    Drug: SHR7280 · Drug: Placebo oral tablet

  • Experimental
    SHR7280 dose 4

    oral administration for 21days,Phase I

    Drug: SHR7280 · Drug: Placebo oral tablet

  • Active comparator
    SHR7280 low dose

    oral administration for 84days,Phase II

    Drug: SHR7280

  • Active comparator
    SHR7280 high dose

    oral administration for 84days, Phase II

    Drug: SHR7280

  • Placebo comparator
    Placebo

    oral administration for 84days, Phase II

    Drug: Placebo oral tablet

Interventions

  • treatment

  • DrugPlacebo oral tablet

    blank control

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse events

    Phase I

    Time frame: Pre-dose to 28±2 days after dose administration

  2. Change From Baseline in the 7-day mean score for pelvic pain as measured by VAS at weeks 12

    Phase II daily assessment of dysmenorrhea score on a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) using an e-Diary.

    Time frame: Baseline and weeks 12

Secondary outcomes

  1. PK markers of SHR7280: area under the plasma concentration versus time curve (AUC)

    Phase I \& II

    Time frame: At pre-defined intervals from initial dose through final study visit

  2. PK markers of SHR7280: time to maximum plasma concentration(Tmax)

    Phase I \& II

    Time frame: At pre-defined intervals from initial dose through final study visit

  3. PK markers of SHR7280: maximum plasma concentration(Cmax)

    Phase I \& II

    Time frame: At pre-defined intervals from initial dose through final study visit

  4. PK markers of SHR7280: half-time(t1/2)

    Phase I \& II

    Time frame: At pre-defined intervals from initial dose through final study visit

  5. PK markers of SHR7280: apparent clearance(CL/F)

    Phase I \& II

    Time frame: At pre-defined intervals from initial dose through final study visit

  6. PK markers of SHR7280: apparent volume of distribution(Vz/F)

    Phase I \& II

    Time frame: At pre-defined intervals from initial dose through final study visit

  7. PD markers of SHR7280: Concentration of Estradiol(E2)

    Phase I \& II

    Time frame: At pre-defined intervals from initial dose through final study visit

  8. PD markers of SHR7280: Concentration of Progesterone(P)

    Phase I \& II

    Time frame: At pre-defined intervals from initial dose through final study visit

  9. PD markers of SHR7280: Concentration of Follicle stimulating hormone(FSH)

    Phase I \& II

    Time frame: At pre-defined intervals from initial dose through final study visit

  10. PD markers of SHR7280: Concentration of Luteinizing hormone(LH)

    Phase I \& II

    Time frame: At pre-defined intervals from initial dose through final study visit

  11. Change From Baseline in the 7-day mean score for pelvic pain as measured by VAS

    Phase II

    Time frame: Baseline and weeks 4、8

  12. Change From Baseline in the Monthly Mean score for pelvic pain as measured by VAS

    Phase II

    Time frame: Baseline and weeks 4、8、12

  13. Change From Baseline in the Monthly Mean Dysmenorrhea Score

    Phase II

    Time frame: Baseline and weeks 8、12

  14. Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score and Dyspareunia Score

    Phase II

    Time frame: Baseline and weeks 4、8、12

  15. Change from baseline to monthly analgesic use to treat endometriosis-associated pain

    Phase II

    Time frame: Baseline and weeks 4、8、12

  16. Patient Global Impression of Change (PGIC) score at week 12

    Phase II

    Time frame: Week 12

  17. Adverse events

    Time frame: during Pre and 28±3 days after dose administration

07

Study locations

1 site
  • Peking University Third Hospital
    Peking, Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in May 2024, 45 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2020
First posted
Jun 5, 2020
StartActual
Jul 30, 2020
Primary completionActual
May 14, 2024
CompletionActual
May 14, 2024
Last update
Jul 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04417972
Responsible party
Sponsor
First posted
Jun 5, 2020
Start date
Jul 30, 2020
Primary completion
May 14, 2024
Completion
May 14, 2024
Last update
Jul 8, 2024

Study contacts

Hongyan Guo, PhD
principal investigator · Peking University Third Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GnRH Antagonist SHR7280

Start the discussion